Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy (Review)
- Authors:
- Xiu‑Yong Liao
- Chao‑Yuan Liu
- Jian‑Feng He
- Li‑Shu Wang
- Tao Zhang
-
Affiliations: Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, Department of Neurosurgery, Chongqing Qianjiang Central Hospital, Chongqing 409000, P.R. China, Department of General Surgery, Chongqing Qianjiang Central Hospital, Chongqing 409000, P.R. China, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA - Published online on: September 19, 2019 https://doi.org/10.3892/ol.2019.10893
- Pages: 5011-5021
-
Copyright: © Liao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Arnold M, Soerjomataram I, Ferlay J and Forman D: Global incidence of esophageal cancer by histological subtype in 2012. Gut. 64:381–387. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Edgren G, Adami HO, Weiderpass E and Nyrén O: A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 62:1406–1414. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, et al: Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: Part 1. Esophagus. 16:1–24. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lin DC, Wang MR and Koef HP: Genomic and epigenomic aberrations in esophageal squamous cell carcinoma and implications for patients. Gastroenterology. 154:374–389. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sawada G, Niida A, Uchi R, Hirata H, Shimamura T, Suzuki Y, Shiraishi Y, Chiba K, Imoto S, Takahishi Y, et al: Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology. 150:1171–1182. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Talukdar FR, di Pietro M, Secricer M, Moehler M, Goepgert K, Lima SSC, Pinto LFR, Hendricks D, Parker MI and Herceg Z: Molecular landscape of esophageal cancer: Implications for early detection and personalized therapy. Ann NY Acad Sci. 1434:342–359. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pakkala S and Ramalingam SS: Personalized therapy for lung cancer: Striking a moving target. JCI Insight. 3:1208582018. View Article : Google Scholar : PubMed/NCBI | |
|
Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P, Samallin E, Boige V, Malka D and Gelli M: Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol. 11:17588359198564942019. View Article : Google Scholar : PubMed/NCBI | |
|
Lam KO and Kwong DLW: Target therapy for esophageal adenocarcinoma. Methods Mol Biol. 1756:51–65. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, et al: Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 18:640–653. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cunningham D, Tebbutt NC and Davidenko I: Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastresophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol. 33 (Suppl 15):40002017. View Article : Google Scholar | |
|
Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, et al: Lapatinib in combination with capecitabine plus oxaliplatin in Human Epidermal Growth Factor Receptor 2-positive advanced or metastatic gastric, esophageal, or gastresophageal adenocarcinoma: TRIO-013/LOGiC-A randomized phase III trial. J Clin Oncol. 34:443–451. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Karlsson AK and Saleh SN: Checkpoint inhibitors for malignant melanoma: A systematic review and meta-analysis. Clin Cosmet Investig Dermatol. 10:325–339. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Herzberg B, Campo MJ and Gainor JF: Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist. 22:81–88. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Raufi AG and Klempner SJ: Immunotherapy for advanced gastric and esophageal cancer: Preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol. 6:561–569. 2015.PubMed/NCBI | |
|
Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, Hironaka S, Hara H, Satoh T, Iwasa S, et al: Nivolumab treatment for oesophageal squamous-cell carcinoma: An open-label, multicentre, phase 2 trial. Lancet Oncol. 18:631–639. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kojima T and Doi T: Immunotherapy for esophageal squamous cell carcinoma. Curr Oncol Rep. 19:332017. View Article : Google Scholar : PubMed/NCBI | |
|
Kang J, Demaria S and Formenti S: Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 4:512016. View Article : Google Scholar : PubMed/NCBI | |
|
Weichselbaum RR, Liang H, Deng L and Fu YX: Radiotherapy and immunotherapy: A beneficial liaison? Nat Rev Clin Oncol. 14:365–379. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Prasad NR, Karthigeyan M, Vikram K, Parthasarathy R and Reddy KS: Palliative radiotherapy in esophageal cancer. Indian J Surg. 77:34–38. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Matuschek C, Bölke E, Zahra T, Knoefel WT, Peiper M, Budach W, Erhardt A, Scherer A, Baldus SE, Gerber PA, et al: Gattermann N, Orth K. Trimodal therapy in squamous cell carcinoma of the esophagus. Eur J Med Res. 16:437–444. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Baskar R, Dai J, Wenlong N, Yeo R and Yeoh KW: Biological response of cancer cells to radiation treatment. Front Mol Biosci. 1:242014. View Article : Google Scholar : PubMed/NCBI | |
|
Gong J, Le TQ, Massarelli E, Hendifar AE and Tuli R: Radiation therapy and PD-1/PD-L1 blockade: The clinical development of an evolving anticancer combination. J Immunother Cancer. 6:462018. View Article : Google Scholar : PubMed/NCBI | |
|
Wan S, Pestka S, Jubin RG, Lyu YL, Tsai YC and Liu LF: Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS One. 7:e325422012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W and Lin SH: Combining immunotherapy and radiotherapy for cancer treatment: Current challenges and future directions. Front Pharmacol. 9:1852018. View Article : Google Scholar : PubMed/NCBI | |
|
Persa E, Balogh A, Sáfrány G and Lumniczky K: The effect of ionizing radiation on regulatory T cells in health and disease. Cancer Lett. 368:252–261. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Facciabene A, Motz GT and Coukos G: T-regulatory cells: Key players in tumor immune escape and angiogenesis. Cancer Res. 72:2162–2171. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S and Sun X, Luo J, Zhu H, Yang X, Guo Q, Song Y and Sun X: Effects of radiation on T regulatory cells in normal states and cancer: Mechanisms and clinical implications. Am J Cancer Res. 5:3276–3285. 2015.PubMed/NCBI | |
|
Tang J, Shalabi A and Hubbard-Lucey VM: Comprehensive analysis of the clinical immune-oncology landscape. Ann Oncol. 29:84–91. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Marin-Algarra S, Mandal R, Sharfman WH, et al: Tumor and microenvironment evoluation during immunotherapy with nivolumab. Cell. 171:934–949.e16. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kono K, Mimura K, Yamada R, Ujiie D, Hayase S, Tada T, Hanayama H, Min AKT, Shibata M, Momma T, et al: Current status of cancer immunotherapy for esophageal squamous cell carcinoma. Esophagus. 15:1–9. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Memarnejadian A, Meilleur CE, Shaler CR, Khazaie K, Bennink JR, Schell TD and Haeryfar SMM: PD-1 blockade promotes epitope spreading in anticancer CD8+ T cell responses by preventing fratricidal death of subdominant clones to relieve immunodomination. J Immunol. 199:3348–3359. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tanaka K, Miyata H, Sugimura K, Kanemura T, Hamada-Uematsu M, Mizote Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, et al: Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Sci. 107:726–733. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Deng H, Lu M, Xu B, Wang Q, Jiang J and Wu C: B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. Int J Clin Exp Pathol. 7:6015–6023. 2014.PubMed/NCBI | |
|
Wang X, Teng F, Kong L and Yu J: PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 9:5023–5039. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, Peng J, Gao L, Liang X and Ma C: Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 36:6143–6153. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Leng C, Li Y, Qin J, Ma J, Liu X, Cui Y, Sun H, Wang Z, Hua X, Yu Y, et al: Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells. Oncol Rep. 35:699–708. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hatogai K, Kitano S, Fujii S, Kojima T, Daiko H, Nomura S, Yoshino T, Ohtsu A, Takiguchi Y, Doi T and Ochiai A: Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma. Oncogarget. 7:47252–47264. 2016. | |
|
Jiang D, Song Q, Wang H, Huang J, Wang H, Hou J, Li X, Xu Y, Sujie A, Zeng H, et al: Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma. Oncogarget. 8:8315–8329. 2017. | |
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al: Nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S and Tsuta K: Immunohistochemical status of PD-L1 in thymoma and thymic carci-noma. Lung Cancer. 88:154–159. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fay AP, Signoretti S, Callea M, Telό GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, et al: Programmed death ligand-1 expression in adrenocortical carcinoma: An exploratory biomarker study. J Immunother Cancer. 3:32015. View Article : Google Scholar : PubMed/NCBI | |
|
Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H and Kwon ED: B7-H1 expression in malig-nant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 9:1036–1040. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, et al: PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with in ammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 1:54–63. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Conway JR, Kofman E, Mo SS, Elmarakeby H and Van Allen E: Genomics of response to immune checkpoint therapies for cancer: Implications for precision medicine. Genome Med. 10:932018. View Article : Google Scholar : PubMed/NCBI | |
|
Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H, Yuan S, Koshiji M, Csiki I and Bennouna J: Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: Preliminary results from KEYNOTE-028. J Clin Oncol. 33 (15 Suppl):S40102015. View Article : Google Scholar | |
|
Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H, Saraf S, Koshiji M, Csiki I and Bennouna J: Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab. J Clin Oncol. 34 (15 Suppl):S40462016. View Article : Google Scholar | |
|
Stenger M: Immunotherapy in Advanced Esophageal Carcinoma. The ASCO Post. 2017, https://www.ascopost.com/News/58296November 29–2017 | |
|
Doi T, Bennouna J, Shen L, Enzinger PC, Wang R, Csiki I, Koshiji M and Shah MA: KEYNOTE-181: Phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma. J Clin Oncol. 34 (15 Suppl):2017. | |
|
Shah MA, Kojima T, Enzinger PC, Hochhauser D, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, et al: Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study. J Clin Oncol. 36 (15 Suppl):S40492018. View Article : Google Scholar | |
|
Kitagawa Y, Doki Y, Kato K and Ura T: Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07). Anna Oncol. 28 (Suppl 5):v209–v268. 2017. | |
|
Yuriy Y, Alexander PO, Calvo E, Joseph W, Kim, Antonio PA, Sharma P and Johanna KP: Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. J Clin Oncol. 35 (Suppl 15):40142017. View Article : Google Scholar | |
|
Greally M, Molena D, Sihag S, Wu Abraham JC, Shah PM, Fein Carly, Capanu M, Kelsen DP, Janjigian YY, Ilson DH, et al: Phase Ib/II trial of durvalumab and chemoradiation (CRT) with carboplatin/paclitaxel for esophageal and gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol. 4:1722018. View Article : Google Scholar | |
|
Chung HC, Arkenau HT, Wyrwicz L, Oh DY, Lee KW, Infante JR, Chin KM, Heydebreck AV, Kang YK and Safran H: Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer. J Clin Oncol. 34 (4 Suppl):S1672016. View Article : Google Scholar | |
|
Smyth E and Thuss-Patience PC: Immune checkpoint inhibition in gastro-oesophageal cancer. Oncol Res Treat. 41:272–280. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bang Y, Golan T, Lin CC, Kang YK, Wainberg ZA, Wasserstrom H, Jin J, Mi G, McNeely SC, Laing N, et al: Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D). J Clin Oncol. 36 (4 Suppl):S922018. View Article : Google Scholar | |
|
Taieb J, Moehler M, Boku N, Ajani JA, Yañez Ruiz E, Ryu MH, Guenther S, Chand V and Bang YJ: Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treat Rev. 66:104–113. 2016. View Article : Google Scholar | |
|
Mole RH: Whole body irradiation-radiobiology or medicine? Br J Radiol. 26:234–241. 1953. View Article : Google Scholar : PubMed/NCBI | |
|
Abuodeh Y, Venkat P and Kim S: Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 40:25–37. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Siva S, MacManus MP, Martin RF and Martin OA: A Abscopal effects of radiation therapy: A clinical review for the radiobiologist. Cancer Lett. 356:82–90. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Van Limbergen EJ, De Ruysscher DK, Olive Pimentel V, Marcus D, Berbee M, Hoeben A, Rekers N, Theys J, Yaromina A, Dubois LJ and Lambin P: Combining radiotherapy with immunotherapy: The past, the present and the future. Br J Radiol. 90:201701572017. View Article : Google Scholar : PubMed/NCBI | |
|
Jing W, Gershan JA, Weber J, Tlomak D, Mcolash L, Sabatos-Peyton C and Johnson BD: Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer. 3:22015. View Article : Google Scholar : PubMed/NCBI | |
|
Salama AK, Postow MA and Salama JK: Irradiation and immunotherapy: From concept to the clinic. Cancer. 122:1659–1671. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Reynders K, Illidge T, Siva S, Chang JY and De Ruysscher D: The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 41:503–510. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al: Radiation and dual checkpoint blockade activates non-redundant immune mechanisms in cancer. Nature. 520:373–377. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Schoenhals JE, Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouka E, Chang JY, Hahn SM and Welsh JW: Preclinical rationale and clinical considerations for radiotherapy plus immunotherapy: Going beyond local control. Cancer J. 22:130–137. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Son CH, Fleming GF and Moroney JW: Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. Cancer Manag Res. 9:553–563. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Frey B, Rückert M, Deloch L, Rühle PF, Derer A, Fietkau R and Gaipl US: Immunomodulation by ionizing radiation-impact for design of radio- immunotherapies and for treatment of inflammatory diseases. Immunol Rev. 280:231–248. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lhuillier C, Rudqvist NP, Elemento O, Formenti SC and Demaria S: Radiation therapy and anti-tumor immunity: Exposing immunogenic mutations to the immune system. Genome Med. 11:402019. View Article : Google Scholar : PubMed/NCBI | |
|
Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC and Seong J: Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget. 8:41242–41255. 2017.PubMed/NCBI | |
|
Oweida A, Lennon S, Calame D, Korpela S, Bhatia S, Sharma J, Graham C, Binder D, Serkova N, Raben D, et al: Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology. 6:e13561532017. View Article : Google Scholar : PubMed/NCBI | |
|
Aguilera T, Rafat M, Kariolis M, Eyben RV, Graves E and Giaccia A: Tumor immunologic heterogeneity influences response to radiation and combination immunotherapy. J Immunother Cancer. 3:P3452015. View Article : Google Scholar | |
|
Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, Deweese TL and Drake CG: Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 3:345–355. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 124:687–695. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Asna N, Livoff A, Batash R, Debbi R, Schaffer P, Rivkind T and Schaffer M: Radiation therapy and immunotherapy-a potential combination in cancer treatment. Curr Oncol. 25:e454–e460. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lazzari C, Karachaliou N, Bulotta A, Viganó M, Mirabile A, Brioschi E, Santarpia M, Gianni L, Rosell R and Gregorc V: Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: Is this the beginning of the end for cancer? Ther Adv Med Oncol. 10:17588359187620942018. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed KA, Stallworth DG, Kim Y, Johnstone PA, Harrison LB, Caudell JJ, Yu HH, Etame AB, Weber JS and Gibney GT: Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol. 27:434–441. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Qian JM, Yu JB, Kluger HM and Chiang VL: Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 122:3051–3058. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, et al: Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 124:98–103. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen MF, Chen PT, Chen WC, Lu MS, Lin PY and Lee KD: The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression. Oncotarget. 7:7913–7924. 2016.PubMed/NCBI | |
|
Stahl M and Budach W: Definitive chemoradiotherapy. J Thorac Dis. 9 (Suppl 8):S792–S798. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Matzenauer M, Vrána D, Vlachová Z, Aujesky R, Vrba R, Neoral C and Melichar B: Stereotactic radiotherapy in the treatment of local recurrences of esophageal cancer. Oncol Lett. 13:1807–1810. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, et al: Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 36:1611–1618. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wu P, Wu D, Li L, Chai Y and Huang J: PD-L1 and survival in solid tumors: A meta-analysis. PLoS One. 10:e01314032015. View Article : Google Scholar : PubMed/NCBI | |
|
Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK and Iyer AK: PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol. 8:5612017. View Article : Google Scholar : PubMed/NCBI | |
|
Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T and Alix-Panabières C: Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 9:1773–1782. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ilié M, Szafer-Glusman E, Hofman V, Chamorey E, Lalvee S, Selva E, Leroy S, Marquette CH, Kowanetz M, Hedge P, et al: Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann Oncol. 29:193–199. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O, Mastromartino M, Del Bene G, Prete A, Longo F, et al: Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor nivolumab. Sci Rep. 6:317262016. View Article : Google Scholar : PubMed/NCBI | |
|
Guibert N, Delaunay M, Lusque A, Boubekeur N, Rouquette I, Clermont E, Mourlanette J, Gouin S, Dormoy I, Favre G, et al: PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer. 120:108–112. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yue C, Jiang Y, Li P, Wang Y, Xue J, Li N, Li D, Wang R, Dang Y, Hu Z, et al: Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. Oncoimmunology. 7:e14381112918. View Article : Google Scholar | |
|
Zhu X and Lang J: Soluble PD-1 and PD-L1: Predictive and prognostic significance in cancer. Oncotarget. 8:97671–97682. 2017.PubMed/NCBI | |
|
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, et al: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 7:1842019. View Article : Google Scholar : PubMed/NCBI | |
|
Califano J, Leong PL, Koch WM, Eisenberger CF, Sidransky D and Westra WH: Second esophageal tumors in patients with head and neck squamous cell carcinoma: An assessment of clonal relationships. Clin Cancer Res. 5:1862–1867. 1999.PubMed/NCBI | |
|
The Cancer Genome Atlas Research Network, . Integrated genomic characterization of oesophageal carcinoma. Nature. 541:169–175. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Predina JD, Judy B, Aliperti LA, Fridlender ZG, Blouin A, Kapoor V, Laguna B, Nakagawa H, Rustgi AK, Aguilar L, et al: Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models. Cancer Gene Ther. 18:871–883. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sharabi AB, Lim M, DeWeese TL and Drake CG: Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 16:e498–509. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Marciscano AE, Walker JM, McGee HM, Kim MM, Kunos CA, Monjazeb AM, Shiao SL, Tran PT and Ahmed MM: Incorporating radiation oncology into immunotherapy: Proceedings from the ASTRO-SITC-NCI immunotherapy workshop. J Immunother Cancer. 6:62018. View Article : Google Scholar : PubMed/NCBI | |
|
Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G and Zitvogel L: Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy. Anna Oncol. 27:1482–1492. 2016. View Article : Google Scholar | |
|
Tang H, Qiao J and Fu YX: Immunotherapy and tumor microenvironment. Cancer Lett. 370:85–90. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Schaaf MB, Garg AD and Agostinis P: Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 9:1152018. View Article : Google Scholar : PubMed/NCBI | |
|
Hendry SA, Farnsworth RH, Solomon B, Achen MG, Stacker SA and Fox SB: The role of the tumor vasculature in the host immune response: Implications for therapeutic strategies targeting the tumor microenvironment. Front Immunol. 7:6212016. View Article : Google Scholar : PubMed/NCBI | |
|
Kallman RF and Dorie MJ: Tumor oxygenation and reoxygenation during radiation therapy: Their importance in predicting tumor response. Int J Radiat Oncol Biol Phys. 12:681–685. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang W, Chan CK, Weissman IL, Kim BYS and Hahn SM: Immune priming of the tumor microenvironment by radiation. Trends Cancer. 2:638–645. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 15:7412–7420. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Somarouthu B, Lee SI, Urban T, Sadow CA, Harris GJ and Kambadakone A: Immune-related tumour response assessment criteria: A comprehensive review. Br J Radiol. 91:201704572018. View Article : Google Scholar : PubMed/NCBI | |
|
Hoos A, Wolchok JD, Humphrey RW and Hodi FS: CCR 20th anniversary commentary: Immune-related response criteria-capturing clinical activity in immuno-oncology. Clin Cancer Res. 21:4989–4991. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, et al: Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 34:1510–1517. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Postow MA, Sidlow R and Hellmann MD: Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 378:158–168. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yovino S and Grossman SA: Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. CNS Oncol. 1:149–154. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez DR, Welsh J, Cox JD, Crane CH, Hsu CC and Lin SH: Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy. Int J Radiat Oncol Biol Phys. 99:128–135. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yamashita H, Haga A, Takenaka R, Kiritoshi T, Okuma K, Ohtomo K and Nakagawa K: Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer. Radiat Oncol. 11:42016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen HY, Ma XM, Ye M, Hou YL, Xie HY and Bai YR: Esophageal perforation during or after conformal radiotherapy for esophageal carcinoma. J Radiat Res. 55:940–947. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Roeder F, Nicolay NH, Nguyen T, Saleh-Ebrahimi L, Askoxylakis V, Bostel T, Zwicker F, Debus J, Timke C and Huber PE: Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Oncol. 9:1912014. View Article : Google Scholar : PubMed/NCBI | |
|
Hong MH, Kim H, Park SY, Kim DJ, Lee CG, Cho J, Kim JH, Kim HR, Kim YH, Park SR and Cho BC: A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC). J Clin Oncol. 37 (15 Suppl):S40272019. View Article : Google Scholar | |
|
Katz M, Bauer TW, Varadhachary G, Acquavella N, Petroni G, Bullock T, Slingluff CL and Rahma OE: A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer. J Clin Oncol. 3 (Suppl 2):P1672015. | |
|
Van Hagen P, Hulshof MC, Van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative chemora-diotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
U.S. Department of Health and Human Services, . Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5×7.pdfNovember 27–2017 |
